Investegate |RedHill Biopharma Announcements | RedHill Biopharma: RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
Investegate announcements from RedHill Biopharma, RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
Source: investegate.co.uk
Page 20 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Expanded Access Program Today - Breaking & Trending Today
BioVentrix® Names Dr. Ori Ben-Yehuda as Chief Medical Officer
/PRNewswire/ -- BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated...
Source: prnewswire.com
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com
FDA Agrees to Expanded Access Program for the BioVentrix® Revivent TC® System for the Treatment of Ischemic Heart Failure
/PRNewswire/ -- BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated...
Source: prnewswire.com
Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer
U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for adagrasib in combination with cetuximab in patients with KRASG12C-mutated advanced colorectal cancer whose... | December 21, 2022
Source: marketscreener.com